SCHEMBL30287689

SCHEMBL30287689

OC1[C@H](O)CN(C[C@@H]2CCN(c3nc(C(F)(F)F)cs3)C2)C[C@@H]1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCAT P04180 2/20 0.41
▸ CTSB P07858 1/20 0.36
▸ CTSS P25774 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ OGA O60502 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ KHK P50053 1/20 0.32
▸ PIM1 P11309 1/20 0.32
▸ GBA1 P04062 2/20 0.32
▸ CXCR3 P49682 4/20 0.31
▸ SCD O00767 1/20 0.31
▸ L3MBTL1 Q9Y468 2/20 0.31
▸ AR P10275 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30287722 1.00 LCAT (0.41) LCATCTSBCTSSCTSKKCNH2
SCHEMBL24008578 1.00 LCAT (0.41) LCATCTSBCTSSCTSKKCNH2
SCHEMBL26778003 1.00 LCAT (0.41) LCATCTSBCTSSCTSKKCNH2
SCHEMBL30287747 0.93 LCAT (0.38) LCATCTSBCTSSCTSKKCNH2
SCHEMBL24008489 0.93 LCAT (0.38) LCATCTSBCTSSCTSKKCNH2
SCHEMBL24008444 0.93 LCAT (0.38) LCATCTSBCTSSCTSKKCNH2
SCHEMBL30287704 0.93 LCAT (0.38) LCATCTSBCTSSCTSKKCNH2
SCHEMBL24008942 0.90 LCAT (0.40) LCATCTSBCTSSCTSKKCNH2
SCHEMBL24008575 0.87 LCAT (0.41) LCATCTSBCTSSCTSKKCNH2
SCHEMBL22668909 0.84 LCAT (0.38) LCATCTSBCTSSCTSKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4146623-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP claimed
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS INC. (CA) 2026-01-20 — — US disclosed
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US disclosed
EP-4146623-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA LCAT 175/4885CTSB 44/4885CTSS 57/4885
US-12528773-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, GAA LCAT 484/4885CTSB 136/4885CTSS 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback